Guardant HealthFRA:5GH +14.10%67 Market Cap is €19,559.3 Mil as of Jul. 03, 2026. GuruFocus rates FRA:5GH with a GF Score™ of 67/100 and a GF Value™ of €53.89 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Guardant Health ranks better than 93.58% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Guardant Health's share price for the quarter that ended in Mar. 2026 was €75.34. Guardant Health's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 131.5 Mil. Therefore, Guardant Health's market cap for the quarter that ended in Mar. 2026 was €9,908.3 Mil.
Guardant Health's quarterly market cap
increased
from Sep. 2025 (€6,570.3 Mil) to Dec. 2025 (€11,192.8 Mil) but then
declined
from Dec. 2025 (€11,192.8 Mil) to Mar. 2026 (€9,908.3 Mil).
Guardant Health's annual market cap
increased
from Dec. 2023 (€3,040.8 Mil) to Dec. 2024 (€3,589.6 Mil) and
increased
from Dec. 2024 (€3,589.6 Mil) to Dec. 2025 (€11,192.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Guardant Health's Enterprise Value for Today is €20,087.7 Mil.
Guardant Health (FRA:5GH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Guardant Health Market Cap Related Terms
Guardant Health Market Cap Historical Data
* Premium members only.
The historical data trend for Guardant Health's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Market Cap distribution charts can be found below:
* The bar in red indicates where Guardant Health's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Guardant Health's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (FRA:5GH) has a Market Cap of €19,559.3 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #14 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 6.4%.
Is Guardant Health's Market Cap too high?
Guardant Health's current Market Cap is €19,559.3 Mil. Based on the distribution chart, Guardant Health ranks #14 out of 218 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Guardant Health has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Market Cap compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #14 out of 218 companies for Market Cap. This places Guardant Health in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 58.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.14, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current Market Cap is €19,559.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (FRA:5GH) is currently considered Significantly Overvalued. The stock's GF Value™ is €53.89, compared to a current price of €149.34 — trading 177.1% above its estimated fair value. The current Market Cap is €19,559.3 Mil. Guardant Health's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Guardant Health (FRA:5GH), the current Market Cap is €19,559.3 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (FRA:5GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of €149.34 is trading 177.1% above its estimated GF Value™ of €53.89.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for FRA:5GH:
Market Cap: €19,559.3 Mil
GF Value™: €53.89 vs. price of €149.34 (177.1% above fair value)
No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score
Get the complete analysis for FRA:5GH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GH has been successfully added to your 
